Loading...
ASCO Lung Cancer 20212025-01-27T17:44:02+01:00

ASCO Lung Cancer 2021 – virtual

Lecture Board: Maximilian Hochmair, MD; Donald Harvey, PharmD; Martin Reck, MD, PhD

Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ASCO 2021

ASCO 2021 English Lung Cancer Download

Full report (english)

ASCO 2021 Mandarin Lung Cancer Download

Full report (mandarin)

ASCO 2021 Japanese Lung Cancer Download

Full report (japanese)

EXPERT VIDEOS

All video interviews from ASCO 2021

David T. Cooke talks about health equity and health disparities relating to lung cancer management in the western world. He explains which factors based on ethnicity are likely to affect outcomes of lung cancer patients and how health disparities might be tackled in the long run at the public health level.

Ferdinandos Skoulidis summarizes why the development of KRASG12C targeted therapies failed in the past, relates to new developments in the field of KRASG12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.

Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.

Donald R. Harvey discusses lung cancer from the point of view of clinical pharmacology, targets in the area of antibody-drug conjugates, the role of proteolysis targeting chimeras (PROTACs) in the treatment landscape, highlights mechanisms of resistance to small molecule inhibitors and draws attention to clinical trial design to better meet the demands of modern drug development.

Luis G. Paz-Ares explains which notable developments are taking place in the field of small-cell lung cancer with respect to new targets and targeted agents, how chemotherapeutic standards will change in the management of patients with small-cell lung cancer and highlights the most relevant findings presented at ASCO 2021 in terms of targeted therapies.

A range of relevant and potentially practice-changing findings was presented in the field of lung cancer. Immunotherapy and targeted-therapy strategies are now being explored either before or after surgery for early stage disease, with multiple challenges in determining what is and is not a transformative approach. (ASCO 2020)

D. Ross Camidge • MD • PhD, Director of Thoracic Oncology, University of Colorado, Aurora, Colorado, USA National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)
Go to Top